|
Patient
|
CD4 T cell count before ART cells/μl
|
CD4 T cell count at presentation of IRIS cells/μl
|
Fold change in CD4 T cell counts from baseline to IRIS presentation
|
CD4 T cell count after remission of IRIS cells/μl
|
HIV-1 RNA at presentation of IRIS copies/ml
|
Reason for admission
|
Time on therapy*
|
Therapy
|
|---|
|
1
|
7
|
69
|
9.86
|
202
|
U/D
|
MAC
|
8
|
d4T+ddI+NFV+ImRx
|
|
2
|
37
|
70
|
1.89
|
140
|
U/D
|
MAC
|
12
|
AZT+3TC+IDV+ImRx
|
|
3
|
4
|
45
|
11.25
|
93
|
U/D
|
MAC
|
18
|
d4T+ddI+NFV+ImRx
|
|
4
|
90
|
280
|
3.11
|
601
|
U/D
|
MAC
|
8
|
AZT+3TC+EFV+ImRx
|
- *Time in months from initiation of potent ART until diagnosis of IRIS. Drugs used in ART regime: Nucleoside analogues; Stavudine (d4T), Didanosine (ddI), Lamivudine (3TC) and Zidovudine (AZT) Protease inhibitors; Nelfinavir (NFV), Indinavir (IDV), or Non-nucleoside reverse transcriptase inhibitor; Efavirenz (EFV); ImRx = immunotherapy; MAC = Mycobacterium avium complex.
